emavusertib + venetoclax

**Emavusertib + venetoclax** is a combination therapy under clinical investigation for the treatment of acute myeloid leukemia (AML), particularly in patients who have measurable residual disease (MRD) following frontline therapy with azacitidine and venetoclax. Emavusertib is a novel, oral small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), and also inhibits FMS-like tyrosine kinase 3 (FLT3) and CDC-like kinases (CLK1/2/4). Modulation of these targets is intended to overcome resistance mechanisms, such as those involving FLT3 mutations or MCL-1 upregulation, that can reduce the effectiveness of venetoclax. Venetoclax is a selective B-cell lymphoma 2 (BCL-2) inhibitor, promoting apoptosis in malignant cells dependent on BCL-2 for survival. The combination is being studied for its potential synergistic anti-leukemic activity, especially in venetoclax-resistant cells, and for the ability to achieve MRD negativity after initial response to venetoclax-containing regimens[1][3][5][7][9].